Stock events for Instil Bio, Inc. (TIL)
Instil Bio, Inc.'s stock price has significantly declined in the past six months. A major event was the discontinuation of AXN-2510's clinical development in January 2026, leading to a strategic shift. Despite these challenges, Q4 2025 earnings surpassed estimates, and the company's cash reserves are expected to fund operations beyond 2027.
Demand Seasonality affecting Instil Bio, Inc.’s stock price
Information regarding demand seasonality for Instil Bio, Inc.'s products and services is not available. As a clinical-stage biopharmaceutical company, its primary focus is on research and development of therapies, rather than the commercial sale of products, which typically exhibit demand seasonality.
Overview of Instil Bio, Inc.’s business
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer, particularly autologous tumor infiltrating lymphocyte (TIL) therapies. Their pipeline includes ITIL-168 for advanced melanoma and ITIL-306, a genetically engineered TIL therapy. The company previously developed AXN-2510/IMM2510 but discontinued its clinical development and collaboration agreement in January 2026.
TIL’s Geographic footprint
Instil Bio, Inc. is headquartered in Dallas, Texas, with research and manufacturing facilities in Los Angeles, California, and Manchester, UK. Their former product candidate was also undergoing trials in China.
TIL Corporate Image Assessment
Instil Bio's brand reputation has likely been affected by its stock underperformance and the termination of the AXN-2510 program. The company's pivot towards acquisitions and in-licensing requires successful execution to restore investor confidence.
Ownership
Instil Bio, Inc. has significant institutional and insider ownership. Major institutional owners include Curative Ventures V LLC, BML Capital Management, LLC, CPMG Inc, Vivo Capital, LLC, Millennium Management Llc, Siren, L.L.C., Vanguard Group Inc, Morgan Stanley, Renaissance Technologies Llc, Dimensional Fund Advisors Lp, and BlackRock, Inc. Key individual and insider shareholders include Curative Ventures V LLC, Vivo Capital IX LLC, Jack Nielsen, R. Kent McGaughy Jr., and Bronson Crouch.
Ask Our Expert AI Analyst
Price Chart
$8.89
